Show us the direct quote from the clinical trials.gov website for the Phase 2b/3 Anavex trial using blarcamesine as a treatment for early stage Alzheimer's disease.
You theory doesn't make sense. The following is part of the exclusion criteria.
Being treated with psychoactive medications on a stable dose for less than 3 month.
So if Aricept was improving the patients cognition that should have happened prior to joining the study and that would be included in the patient's baseline.
Market Data 
Markets 
AI
